Table 2 Comparison of the short-term effects between the two groups
| Â | Complete response (CR) | Partial response (PR) | Stable disease (SD) | Progressive disease (PD) | Objective response rate (ORR) | Disease control rate (DCR) |
|---|---|---|---|---|---|---|
TACE + Sorafenib (n = 116) | 6(5.17%) | 59(50.86%) | 37(31.90%) | 14(12.07%) | 65(56.03%) | 102(87.93%) |
TACE + aptinib (n = 116) | 9(7.76%) | 73(62.93%) | 26(22.41%) | 8(6.90%) | 82(70.69%) | 108(93.10%) |
X2 | Â | Â | Â | Â | 5.366 | 1.808 |
P | Â | Â | Â | Â | 0.021 | 0.179 |